Showing results (411-420 of 421) with videos related to
Sort By:
Pageof 43
Nature Medicine|November 4, 2000
A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivoD DeFeo-Jones, V M Garsky, B K Wong, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 1997
Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bileS K Balani, X Xu, V Pratha, et al.Bioorganic & Medicinal Chemistry Letters|January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitorP E Sanderson, K J Cutrona, B D Dorsey, et al.Journal of Medicinal Chemistry|February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid supportS F Brady, K J Stauffer, W C Lumma, et al.Journal of Medicinal Chemistry|September 9, 2000
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitorsB D Dorsey, C McDonough, S L McDaniel, et al.The British Journal of Surgery|April 5, 2020
Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasionX-P Zhang, K Wang, Y-Z Gao, et al.Journal of Medicinal Chemistry|November 7, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templatesP E Sanderson, T A Lyle, K J Cutrona, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 11, 2022
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical TrialXuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.Pageof 43